Publication | Closed Access

Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Intermediate DoseLymphoid NeoplasiaOncologyMedicineFrail Elderly PatientsPathologyAnti-cancer AgentCancer TreatmentAggressive LymphomaPharmacologyCancer ResearchDrug Resistance